Navigation Links
Omeros Announces Clinical Development Programs for OMS103HP and OMS302
Date:5/19/2011

utcomes measure used in the successful Phase 2 meniscectomy trial.

OMS302 will be evaluated for safety and efficacy in patients undergoing intra-ocular lens replacement surgery. The trials will enroll both cataract surgery and refractive lens exchange patients. This clinical program will involve two randomized, double-blind, placebo-controlled, multicenter trials. The first trial will be conducted in North America and data are expected in the first half of 2012.  Omeros will initiate the second trial in Europe following discussions with regulators to ensure that data collected meet European expectations for marketing approval. The co-primary endpoints for these trials – maintenance of intraoperative pupil dilation (mydriasis) and reduction of postoperative pain – are the same as those achieved in the recently completed 221-patient Phase 2b trial.

Omeros' OMS103HP Program

OMS103HP is Omeros' PharmacoSurgery™ product candidate being developed for use during arthroscopic procedures, including partial meniscectomy surgery, and was designed to provide a multimodal approach to preemptively block the inflammatory cascade induced by arthroscopy. OMS103HP is a proprietary combination of anti-inflammatory/analgesic active pharmaceutical ingredients (APIs), each with well-known safety and pharmacologic profiles. Each of the APIs are components of generic, FDA-approved drugs that have been marketed in the United States as over-the-counter or prescription drug products for over 15 years and have established and well-characterized safety profiles.

In a Phase 2 clinical trial that evaluated OMS103HP in patients undergoing partial meniscectomy surgery, OMS103HP provided clinically meaningful and significantly greater efficacy than vehicle as measured by patient-reported functional scores using the Knee Injury and Osteoarthritis Outcome Score (KOOS), passive knee flexion and visual analog scale pain scores. The patient-
'/>"/>

SOURCE Omeros Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Omeros Corporation Reports First Quarter 2011 Financial Results
2. Omeros Announces Expansion of Potential Indications for PDE7 Inhibitors
3. Omeros Announces Publication of MASP-2 Data in Proceedings of the National Academy of Sciences
4. Omeros Reports Outcome of Phase 3 Trials of OMS103HP
5. Omeros Corporation Reports Fourth Quarter and Year-End 2010 Financial Results
6. Omeros Unlocks Orphan GPCRs Linked to Pancreatic Cancer and Cognitive Disorders
7. Omeros Announces Expansion of Exclusive License to PDE7 Inhibitors from Daiichi Sankyo
8. Omeros Announces Publication of Data From Antifibrinolytic Program
9. Omeros Licenses Novel Antifibrinolytic Agents
10. Omeros Announces Positive Clinical Results of OMS201 in Patients Undergoing Ureteroscopy
11. Omeros to Host Conference Call Monday, October 25 at 4:00 p.m. ET To Provide Corporate Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... SAN FRANCISCO , Aug. 31, 2015  On ... District of Oregon denied motions ... Inc. (NASDAQ: GALE ) and certain of its ... had facilitated a "pump and dump" scheme to artificially ... trading period while the stock price was inflated, sold ...
(Date:8/31/2015)... 31, 2015  Regulatory affairs professionals work at ... are often strict and legislation is ever-changing. The ... for professionals who have a deep understanding of ... product lifecycle and demonstrate its use across various ... California, Irvine Extension , in partnership with the ...
(Date:8/31/2015)... Aug. 31, 2015 Regen BioPharma, Inc. (OTCBB: ... a novel means of delivering its patented (US ... liver tumors utilizing a clinically approved formulation as ... hurdles with gene silencing therapeutics in which the ... the whole body.  By utilizing a local delivery ...
Breaking Medicine Technology:Galena Biopharma, Inc. Stock Alert: Schubert Firm Investigates Potential Breaches of Fiduciary Duty 2UC Irvine Extension Launches New Regulatory Affairs and Compliance Certificate Program 2UC Irvine Extension Launches New Regulatory Affairs and Compliance Certificate Program 3Regen BioPharma, Inc. Develops BORIS Gene Silencing Based Treatment for Unresectable Liver Cancer 2Regen BioPharma, Inc. Develops BORIS Gene Silencing Based Treatment for Unresectable Liver Cancer 3
... Ore.--(BUSINESS WIRE)--Jul 10, 2007 - AVI BioPharma, Inc.,(Nasdaq:AVII) ... target patient enrollment and released six-month,follow-up data from ... trial, currently being held in Germany, was designed ... Resten-MP(TM), when,used in conjunction with the placement of ...
... Fail to Demonstrate Meaningful Placebo Adjusted Weight,Loss; ... July 09, 2007 /PRNewswire-FirstCall/ -- Manhattan,Pharmaceuticals, Inc. ... 2a clinical trials of oral Oleoyl-estrone (OE). ... one,in common obesity and the other in ...
Cached Medicine Technology:AVI BioPharma Partner Cook Medical Announces Completion of Patient,Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of,Cardiovascular Disease 2Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for,Oral Oleoyl-estrone 2Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for,Oral Oleoyl-estrone 3Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for,Oral Oleoyl-estrone 4
(Date:9/1/2015)... Toronto, Canada (PRWEB) , ... ... ... Technologies announce PRO Archiver for Alfresco, a next-generation customer communications archiving ... is built with market-leading technology from Crawford and helps organizations save millions ...
(Date:9/1/2015)... ... , ... Anthony J. Tantillo, Esq., Attorney from William Mattar Law Offices, ... in a row. Through nomination, research and strategic evaluation processes, Tantillo continues to ... New York, Tantillo is a Buffalo State College graduate of 1998. Tantillo went ...
(Date:9/1/2015)... Denver, CO. (PRWEB) , ... September 01, 2015 , ... ... parents and product manufacturers use safety labels and stickers to keep little ones' safety ... every year Baby Safety Month has a particular focus. According to the JPMA's Baby ...
(Date:8/31/2015)... ... September 01, 2015 , ... ... announced the release of ten hours of new premium on-demand video Evidence ... members. , Athletic Trainers certified before 2014 must complete 50 CEUs before December ...
(Date:8/31/2015)... ... August 31, 2015 , ... Sculpted Contours Luxury Medical Aesthetics proudly announces ... and Influence by Modern Luxury’s The Atlantan Magazine. , This award for ... Kathy King. Her idea and vision to bring to Atlanta a true luxury ...
Breaking Medicine News(10 mins):Health News:Introducing Next-Generation Archiving Solution PRO Archiver for Alfresco® 2Health News:Introducing Next-Generation Archiving Solution PRO Archiver for Alfresco® 3Health News:Lightning Labels Can Help Make A Difference This Baby Safety Month 2Health News:Lightning Labels Can Help Make A Difference This Baby Safety Month 3Health News:Evidence Based Practice Courses: CEUs For Athletic Trainers Just Released 2Health News:Sculpted Contours Owner Selected One of Atlanta's Women of Power and Influence by Modern Luxury's The Atlantan Magazine 2Health News:Sculpted Contours Owner Selected One of Atlanta's Women of Power and Influence by Modern Luxury's The Atlantan Magazine 3
... Thermage, Inc.,(Nasdaq: THRM ), a leader ... today that it will present at the First ... New York Hotel. The Company,s,presentation is scheduled for ... Laureen DeBuono, Chief Financial Officer of Thermage, will,review ...
... are taking enough exercise, suggests research published ahead of print in ... kids spend at least an hour a day doing some form ... good health and stave off the risks of subsequent obesity and ... than 5,500 11 year olds in the South West of England ...
... a year in the making, a federal plan ... and safety (EHS) impacts of nanoscale materials has ... as to whether the governments 13-agency nanotechnology research ... research strategy, according to David Rejeski, head of ...
... the nation has invested billions of dollars preparing to ... at risk because they do not account for critical ... themselves. To fix this fundamental flaw, The New ... and toolsavailable at www.redefiningreadiness.net that will enable households, ...
... offers a complete, natural, effective, and, ADA-approved ... , KENNEBUNK, Maine, Sept. 13 Tom,s ... and values-based business, reaffirms its,commitment to safety and ... floss has earned the American Dental Association,s Seal,of ...
... Pedaling to Raise Awareness of Lupus and ... Funds for Lupus Foundation of America, ... James Mason of Houston, Texas, two recent,college graduates, will end ... after biking nearly 4,000 miles from Bellingham,Washington to Charleston, South ...
Cached Medicine News:Health News:Less than 3 percent of UK 11-year-olds take enough exercise 2Health News:Federal research plan to determine nanotech risks fails to deliver 2Health News:Federal research plan to determine nanotech risks fails to deliver 3Health News:Academy releases emergency preparedness tools to enable millions more people to shelter in place 2Health News:Academy releases emergency preparedness tools to enable millions more people to shelter in place 3Health News:Academy releases emergency preparedness tools to enable millions more people to shelter in place 4Health News:Tom's of Maine Tooth Floss Earns American Dental Association's Seal of Acceptance 2Health News:Bike Ride Across the U.S. to End Saturday at Folly Beach 2
Open blade design with aspiration capabilities for removing fluids from the operative site. 19 gauge wire....
Designed to provide open approaches of the keratome to the cornea for either the left or right eye. Lightweight wire design adds to the comfort of the instrument when in place....
Solid 14 mm free-swinging blades, suture posts, and stabilizing disk. Dull finish....
Designed for use with foster enucleation snare (E3670). Package of 12 stainless steel wires. Overall length 5.3 inches....
Medicine Products: